Risk stratification using NT-proBNP and other cardiac biomarkers (e.g., echocardiography and high-sensitivity cardiac troponin T) has identified high-risk participants for heart failure, although a substantial number of participants initially classified as low risk developed heart failure [172]. This evidence concerns the gene NPPB and heart failure.